Browsing Tag
Vicebio
7 posts
Can Sanofi turn molecular clamp technology into a global respiratory vaccine platform beyond RSV?
Can Sanofi turn Vicebio’s molecular clamp tech into a global respiratory vaccine platform? Analysts see multi-pathogen potential beyond RSV by 2030.
August 1, 2025
How much could Vicebio’s $1.15bn acquisition add to Sanofi’s RSV market share by 2030?
Can Sanofi’s $1.15B Vicebio deal help it win 10% of the RSV market by 2030? Analysts weigh in on how combination vaccines could change respiratory care.
July 31, 2025
What makes molecular clamp technology attractive for future combination respiratory vaccines?
Can molecular clamp technology make combination respiratory vaccines more practical than mRNA? Learn how Sanofi plans to use it for multi-pathogen protection.
July 30, 2025
Is Sanofi creating a template for biopharma bolt-on deals with its Vicebio acquisition?
Is Sanofi setting a new standard for biopharma bolt-on deals with its $1.15B Vicebio acquisition? Find out how this strategy could shape future M&A.
July 29, 2025
Will Vicebio’s VXB-241 and VXB-251 give Sanofi an edge in older adult respiratory protection?
Can Sanofi’s VXB-241 and VXB-251 vaccines protect older adults better than single-pathogen RSV shots? Explore how they could reshape respiratory care.
July 28, 2025
Can Sanofi’s molecular clamp bet with Vicebio challenge mRNA leaders in respiratory vaccines?
Can Sanofi’s $1.15B Vicebio deal challenge Pfizer and Moderna’s mRNA RSV dominance? Explore how molecular clamp vaccines could change respiratory protection.
July 25, 2025
Sanofi to acquire Vicebio in $1.15bn deal to expand RSV and hMPV vaccine pipeline
Sanofi doubles down on vaccines and rare immunology with Vicebio and Blueprint acquisitions. Find out how these deals could reshape its growth strategy.
July 22, 2025